Importantly, PAF-R activation by pro-oxidative stressors including the therapeutic agents, augment the growth and impede cancer therapy efficacy in experimental murine melanoma models in a process blocked by cyclooxygenase type 2 (COX-2) inhibitors [16–19]. The gene discussed is PTAFR; the disease is melanoma.